Gemfibrozil improves insulin sensitivity and flow‐mediated vasodilatation in type 2 diabetic patients
Endothelial dysfunction is an early feature of atherosclerosis. The relationship between insulin action and hypertriglyceridaemia on endothelial function is still debated. Materials and Methods
This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity. Ten type 2 diabetic patients were randomised in crossover, double blind fashion, either to GF, 600 mg b.i.d. or placebo, for 12 weeks. Lipid profile, low-density lipoprotein (LDL) distribution and flotation properties, insulin action and flow-mediated vasodilatation (FMD) by brachial artery ultrasound, were assessed. Results
GF decreased serum triglyceride (TG) concentration with an absolute difference of 1·79 ± 1·28 mmol L−1 (P < 0·0016) between active treatment and placebo, and significantly increased serum high-density lipoprotein (HDL) cholesterol (P = 0·0233). No differences were observed in total, intermediate‐density lipoproteins (IDL) , LDL cholesterol concentration and LDL peak buoyancy between treatments. GF also improved SI, an index of insulin action (P = 0·005). The FMD was 7 ± 3% in the baseline condition, 7 ± 2% during placebo and 14 ± 3% after GF (P < 0·006). Conclusions
GF treatment improves both insulin action and flow-mediated vasodilatation in type 2 diabetic patients. The reduction of TG concentration allows the simultaneous correction of two important components of the metabolic syndrome.
Document Type: Research Article
Publication date: July 1, 2001